Search Results - "ROSSINI, D"

Quantum correlations and limit cycles in the driven-dissipative Heisenberg lattice by Owen, E T, Jin, J, Rossini, D, Fazio, R, Hartmann, M J

“…Driven-dissipative quantum many-body systems have attracted increasing interest in recent years as they lead to novel classes of quantum many-body phenomena…”
Get full text

Topological Devil's staircase in atomic two-leg ladders by Barbarino, S, Rossini, D, Rizzi, M, Fazio, R, Santoro, G E, Dalmonte, M

“…We show that a hierarchy of topological phases in one dimension-a topological Devil's staircase-can emerge at fractional filling fractions in interacting…”
Get full text

Ground-state factorization and correlations with broken symmetry by Tomasello, B, Rossini, D, Hamma, A, Amico, L

“…We show how the phenomenon of factorization in a quantum many-body system is of collective nature. To this aim we study the quantum discord Q in the…”
Get full text

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study by Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., Baratelli, C., Tamburini, E., Tampellini, M., Sensi, E., Fucà, G., Volpi, C., Milione, M., Di Maio, M., Fontanini, G., De Braud, F., Falcone, A., Pietrantonio, F.

“…Refining the selection of metastatic colorectal cancer patients candidates for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies beyond RAS…”
Get full text

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., Cremolini, C.

“…The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or…”
Get full text

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials by Cremolini, C., Loupakis, F., Masi, G., Lonardi, S., Granetto, C., Mancini, M.L., Chiara, S., Moretto, R., Rossini, D., Vitello, S., Allegrini, G., Tonini, G., Bergamo, F., Tomasello, G., Ronzoni, M., Buonadonna, A., Bustreo, S., Barbara, C., Boni, L., Falcone, A.

“…FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for metastatic colorectal cancer (mCRC) patients. While several trials investigated the…”
Get full text

Innovative combination of QuEChERS extraction with on-line solid-phase extract purification and pre-concentration, followed by liquid chromatography-tandem mass spectrometry for the determination of non-steroidal anti-inflammatory drugs and their metabolites in sewage sludge by Rossini, D., Ciofi, L., Ancillotti, C., Checchini, L., Bruzzoniti, M.C., Rivoira, L., Fibbi, D., Orlandini, S., Del Bubba, M.

“…For the first time QuEChERS extraction of sewage sludge was combined with the automatic solid-phase pre-concentration and purification of the extract…”
Get full text

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected by Pietrantonio, F., Di Nicolantonio, F., Schrock, A.B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P., Drilon, A., Hechtman, J.F., Christiansen, J., Gowen, K., Frampton, G.M., Gasparini, P., Rossini, D., Gigliotti, C., Kim, S.T., Prisciandaro, M., Hodgson, J., Zaniboni, A., Chiu, V.K., Milione, M., Patel, R., Miller, V., Bardelli, A., Novara, L., Wang, L., Pupa, S.M., Sozzi, G., Ross, J., Di Bartolomeo, M., Bertotti, A., Ali, S., Trusolino, L., Falcone, A., de Braud, F., Cremolini, C.

“…Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to…”
Get full text

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram by Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., Loupakis, F., Spada, D., Cinieri, S., Beretta, G., Falcone, A., de Braud, F., Cremolini, C.

“…Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC)…”
Get full text

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials by Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del Re, M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., Ciardiello, F., Cremolini, C., Martinelli, E.

“…The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of…”
Get full text

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer by Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Murgioni, S., Rossini, D., Marmorino, F., Mennitto, A., Ning, Y., Okazaki, S., Berger, M.D., Miyamoto, Y., Gopez, R., Barzi, A., Yamaguchi, T., Loupakis, F., Lenz, H.-J.

“…Tri-phosphorylated trifluridine (FTD) incorporation into DNA is TAS-102’s main anti-tumor action. We tested whether genetic polymorphisms in homologous…”
Get full text

Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition by Marinelli, D., Sabatini, A., Bengala, E., Ciurluini, F., Picone, V., Santini, D., Pietrantonio, F., Rossini, D., Cremolini, C.

Get full text

Optimal correlations in many-body quantum systems by Amico, L, Rossini, D, Hamma, A, Korepin, V E

“…Information and correlations in a quantum system are closely related through the process of measurement. We explore such relation in a many-body quantum…”
Get full text

Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis by Rossini, D., Pagani, F., Pellino, A., Dell’Aquila, E., Liscia, N., Bensi, M., Germani, M., Masi, G., Moretto, R., Santini, D., Salvatore, L., Scartozzi, M., Lonardi, S., Zucchelli, G., Puglisi, F., Vannini, F., Colombo, C., Falcone, A., Pietrantonio, F., Cremolini, C.

Get full text

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by Rossini, D., Sbrana, A., Bergamo, F., Manai, C., Santini, D., Ghidini, M., Antoniotti, C., Moretto, R., Marmorino, F., Urbano, F., Ronzoni, M., Noventa, S., Randon, G., Carlomagno, C., Latiano, T., Cordio, S., Granetto, C., Cremolini, C., Falcone, A., Antonuzzo, A.

Get full text

TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts) by Cremolini, C., Antoniotti, C., Lonardi, S., Rossini, D., Pietrantonio, F., Cordio, S.S., Murgioni, S., Marmorino, F., Maiello, E., Passardi, A., Masi, G., Tamburini, E., Santini, D., Grande, R., Zaniboni, A., Granetto, C., Loupakis, F., Delliponti, L., Boni, L., Falcone, A.

Get full text

Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies by Zucchelli, G., Marmorino, F., Rossini, D., Aprile, G., Casagrande, M., Lonardi, S., Murgioni, S., Dell’Aquila, E., Tomasello, G., Moretto, R., Antoniotti, C., Borelli, B., Urbano, F., Ronzoni, M., Zaniboni, A., Manglaviti, S., Buonadonna, A., Ritorto, G., Masi, G., Allegrini, G., Falcone, A., Cremolini, C.

Get full text

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC by Cremolini, C., Antoniotti, C., Lonardi, S., Rossini, D., Morano, F., Cordio, S., Bergamo, F., Marmorino, F., Maiello, E., Passardi, A., Masi, G., Tamburini, E., Santini, D., Grande, R., Zaniboni, A., Granetto, C., Murgioni, S., Aprile, G., Delliponti, L., Boni, L., Falcone, A.

Get full text

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO by Rossini, D., Cremolini, C., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Bergamo, F., Danesi, R., Cardellino, G., Tamburini, E., Dell'Aquila, E., Strippoli, A., Masi, G., Tonini, G., Negri, F., Corsi, D., Pella, N., Intini, R., Falcone, A., Santini, D.

Get full text

Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting by Giordano, M., Moretto, R., Giannini, R., Zucchelli, G., Pietrantonio, F., Antoniotti, C., Ugolini, C., Morano, F., Marmorino, F., Sensi, E., Belfiore, A., Rossini, D., Lupi, C., Masi, G., Borelli, B., Ongaro, E., Boccaccino, A., Falcone, A., Cremolini, C., Fontanini, G.

Get full text